ARPP21 identified as major ALS gene in French cohorts

An international team led by researchers in France has confirmed that a gene called ARPP21 is a significant contributor to amyotrophic lateral sclerosis (ALS), the devastating neurological condition that destroys the nerve cells controlling voluntary movement. The findings, published in the journal Acta Neuropathologica, position ARPP21 as the most frequent rare ALS-associated gene in France after the four best-known ALS genes are excluded, and they establish two recurrent variants of the gene as genuinely pathogenic — capable of contributing to disease on their own. For patients and families who have endured years of genetic uncertainty, the work adds a crucial new name to the list of genes that clinicians can now test for, and it opens a fresh window onto the molecular chaos that unfolds inside dying motor neurons.

ALS is the most common adult-onset motor neuron disease, marked by the progressive degeneration of upper and lower motor neurons in the cortex, brainstem, and spinal cord. Patients typically lose the ability to move, speak, swallow, and eventually breathe, with most succumbing to respiratory failure within a few years of diagnosis. Roughly 90 percent of cases are classified as sporadic, arising without any clear family history and presumed to be multifactorial in origin. The remaining 10 percent are inherited in recognizable familial patterns. While decades of genetic discovery have identified the major culprits — hexanucleotide repeat expansions in C9orf72 and mutations in SOD1, TARDBP, and FUS — about one-third of familial ALS cases still have no identified genetic cause. That gap matters enormously, because targeted therapies are already being built around known genes: antisense oligonucleotide treatments designed to reduce toxic SOD1 or FUS protein are now being proposed to selected patients, and every newly validated ALS gene represents a potential future therapeutic target.

The new study began with a large French pedigree in which ALS was transmitted in an autosomal dominant fashion across ten affected individuals. Using whole-exome sequencing, the researchers searched for genetic variants shared by all affected family members, and a single candidate emerged: a variant in ARPP21, the gene encoding cyclic AMP-regulated phosphoprotein 21. The variant, designated c.1586C>T, p.Pro529Leu (p.P529L) on one reference transcript — and corresponding to p.Pro563Leu (p.P563L) on an alternate transcript — changed a conserved proline residue to leucine. Notably, the same variant had recently been flagged as a high-effect ALS-associated variant in the largest whole-exome analysis of ALS conducted to date, which compared 17,919 ALS cases against 200,703 controls. It had also surfaced independently in familial ALS cases from the United Kingdom, the Netherlands, Belgium, and Spain, and was found to cluster among ten patients from seven families in a single north-eastern Spanish province. In several of those earlier reports, however, patients carrying ARPP21 variants also carried variants in other ALS-associated genes, such as GLT8D1, CFAP410, KIF5A, NEK1, or TBK1, leaving open the question of whether ARPP21 was truly driving disease or merely a passenger.

To resolve that question, the French team assembled an impressive clinical and genetic resource: 1,190 patients diagnosed with ALS according to established criteria, all of them free of pathogenic variants in the four major ALS genes. The cohort comprised 300 index cases from independent families with familial ALS — defined as probands with at least one first- or second-degree relative affected by ALS — and 890 patients with apparently sporadic disease. Whole-exome sequencing was performed on DNA from 540 of these patients, including all 300 familial index cases and 240 sporadic cases, the latter including 100 patients who had undergone autopsy and 140 with early-onset disease. In addition, 50 family members were available for segregation analysis, allowing the researchers to trace how the variant moved through pedigrees in lockstep with illness. From this effort, the team characterized 29 patients with ARPP21-linked disease, the largest such series assembled for this gene.

The numbers that emerged are striking. After excluding the four major ALS genes, ARPP21 turned out to be the most frequent rare ALS-associated gene in the French cohort, accounting for 2.7 percent of familial cases and 0.1 percent of sporadic cases. Among the recurrent variants, two stood out: p.P529L (also known as p.P563L) and a second proline-to-leucine substitution, p.P713L (equivalently p.P747L on an alternate transcript). Perhaps the most clinically consequential finding concerns penetrance — the probability that a person carrying a pathogenic variant will actually develop disease. The team calculated that age-dependent penetrance reached 45 percent by age 50 and increased only modestly thereafter, remaining incomplete even at advanced ages. In practical terms, this means that roughly half of people carrying an ARPP21 variant may reach later life without developing ALS, a pattern that complicates genetic counseling but also offers reassurance to at-risk relatives. Incomplete penetrance of this kind may also help explain why ARPP21-linked cases have sometimes appeared sporadic, hiding within families as apparently isolated disease.

Genetics alone could not settle the pathogenicity question, so the researchers turned to the laboratory and the autopsy suite. In cellular models, they examined what the p.P713L mutant protein does inside cells, and the results pointed toward a classic neurodegenerative mechanism. The mutant protein showed a pronounced tendency to aggregate, and that aggregation was associated with hyperphosphorylation of the protein — the addition of excessive phosphate groups, a chemical modification long implicated in the formation of pathological protein clumps in diseases ranging from Alzheimer’s to ALS. Critically, the aggregates colocalized with p62, a well-established marker of autophagy, the cellular waste-disposal system that neurons rely on to clear damaged proteins. When p62 piles up alongside an aggregating protein, it signals that the cell’s clearance machinery is being overwhelmed or subverted, a hallmark of toxic proteinopathy.

The neuropathological examination of brain and spinal cord tissue from a deceased carrier of the p.P529L variant provided an even more direct look at the disease process. The tissue displayed the expected signature of ALS: cytoplasmic aggregates of TDP-43, the RNA-binding protein whose mislocalization and clumping define the pathology of most ALS cases. But the researchers also observed heterogeneous deposits that stained positive for ARPP21 itself. The interpretation demanded nuance. The ARPP21 antibody used in the study also stained structures known as granulovacuolar degenerations — a form of neuronal change associated with general cellular stress rather than any single disease protein. This overlap means that the ARPP21-positive deposits observed may reflect a stressed neuron’s response to injury rather than a specific pathology driven by mutant ARPP21. The authors were careful on this point, and their honesty reflects the challenging reality of neuropathology, where antibody specificity can blur the line between cause and consequence.

Even with that caveat, the weight of evidence now supports ARPP21 as an important ALS-associated gene. The convergence is compelling: the variant segregates with disease in a large pedigree; it recurs in unrelated families across multiple European countries; it appears as a high-effect signal in the largest case-control sequencing study of ALS ever performed; the mutant protein aggregates and hyperphosphorylates in cells; and the affected tissue shows the canonical TDP-43 pathology of ALS. Taken together with previous studies, the team concludes that both p.P529L/p.P563L and p.P713L/p.P747L should be considered pathogenic, ALS-causing variants. The designation is not academic. Genetic diagnosis shapes family planning, eligibility for gene-targeted trials, and the counseling of asymptomatic relatives, and the authors argue that incorporating ARPP21 into routine genetic testing panels for familial ALS could meaningfully improve diagnostic yield.

The study also underscores a broader shift in ALS research. For years, the field revolved around a handful of major genes, leaving hundreds of familial cases without answers. Whole-exome and whole-genome sequencing, applied both to large multi-generation pedigrees and to massive case-control burden analyses, is steadily filling that void, revealing a long tail of rare genetic contributors — each one a thread that can be pulled to unravel disease mechanism. ARPP21 is particularly intriguing in this respect. The gene encodes a phosphoprotein regulated by cyclic AMP, placing it within neuronal signaling pathways rather than among the RNA-processing proteins and protein-quality-control factors that dominate the established ALS gene list. If future work confirms how perturbed cAMP-regulated phosphorylation contributes to motor neuron degeneration, ARPP21 could point to an entirely new axis of ALS biology — and, potentially, to therapeutic strategies unlike those now in development for SOD1 or FUS.

For now, the message for clinicians and geneticists is concrete: ARPP21 belongs on the diagnostic radar. For the families who carry these variants, the finding transforms an unexplained tragedy into a named, testable genetic condition, with all the empowerment and difficult choices that entails. And for researchers, it adds another molecular actor to the crowded stage of motor neuron degeneration, one whose full role — from phosphorylated aggregates to stressed neurons — is only beginning to come into focus. The study, published as an open-access article in Acta Neuropathologica, represents exactly the kind of painstaking, multi-decade, multi-family detective work upon which progress in rare disease genetics depends, and it signals that the era of undiscovered ALS genes is far from over.